Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy

Oncology Reports

Volumn 16, Issue 1, 2006, Pages 57-63

  Faried, Leri S ^a   Faried, Ahmad ^a   Kanuma, Tatsuya ^a   Sano, Takaaki ^a   Nakazato, Tomoko ^a   Tamura, Tomohiro ^a   Kuwano, Hiroyuki ^a   Minegishi, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Activated mammalian target of rapamycin; Cervical cancer; Immunohistochemistry; p Akt; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BIOSYNTHESIS; CYTOPLASM; FEMALE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHORYLATION; PROGNOSIS; UTERINE CERVIX TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYTOPLASM; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 33750742240     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.1.57     Document Type: Article

References (37)

1. Ferlay J, Bray F, Pisani P and Parkin DM: Globocan 2002: Cancer incidence, mortality, and prevalence worldwide International Agency for Research on Cancer Cancer Base 5, Version 2.0. Lyon: IARC 2004.
2. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999. (Pubitemid 29409471)
3. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams CJ: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and analysis. Lancet 358: 781-786, 2001. (Pubitemid 32868726)
4. Benedet JL, Odicino F, Maisonneuve P, et al: Carcinoma of the cervix uteri. J Epidemiol Biostat 6: 7-43, 2001.
5. Coffer PJ, Jin J and Woodgett JR: Protein kinase B (cAkt): a multifunctional mediator of phosphatidylinositol-3 kinase activation. Biochem J 335: 1-13, 1998. (Pubitemid 28477043)
6. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
7. Hidalgo M and Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680-6686, 2000. (Pubitemid 32197708)
8. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC and Thomas G: Mammalian TOR: a homeostatic ATP sensor. Science 294: 1102-1105, 2001. (Pubitemid 33041865)
9. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A and Wasik MA: Activation of mammalian target of rapamycin in transformed lymphocytes is nutrients dependent but independent of akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65: 7800-7808, 2005. (Pubitemid 41297255)
10. Creasman WT: New gynecologic cancer staging. Gynecol Oncol 58: 157-158, 1995.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
12. Freitas S, Moore DH, Michael H and Kelley MR: Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance. Clin Cancer Res 9: 4689-4694, 2003. (Pubitemid 37323270)
13. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S and Gosh PM: Phosphorylation of Akt (Ser 473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64: 5232-5236, 2004. (Pubitemid 39006542)
14. Perez-Tenorio G and Stal O: Southeast Sweden Breast Cancer Group: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545, 2002. (Pubitemid 34185089)
15. Maehama T and Dixon JE: The tumor suppressor PTEN/MMAC1 dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-triphosphate. J Biol Chem 273: 13375-13378, 1998. (Pubitemid 28268370)
16. Su TH, Chang JG, Perng LI, Chang CP, Wei HJ, Wang NM, and Tsai CH: Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer. Gynecol Oncol 76: 193-199, 2000. (Pubitemid 30067194)
17. Cheung TH, Lo KW, Yim SF, et al: Epigenetic and genetic alteration of PTEN in cervical neoplasm. Gynecol Oncol 93: 621-627, 2004. (Pubitemid 38766045)
18. Ma YY, Wei SJ, Lin YC, et al : PIK3CA as an oncogene in cervical cancer. Oncogene 23: 2739-2744, 2000.
19. Nicholson KM and Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14: 381-395, 2002. (Pubitemid 34214843)
20. Lee SH, Kim HS, Park WS, et al: Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 110: 587-592, 2002.
21. David O: Akt and PTEN: new diagnostic markers of non-small cell lung cancer? J Cell Mol Med 5: 430-433, 2001.
22. Zhou X, Tan M, Stone Hawthorne V, et al: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788, 2004. (Pubitemid 39383026)
23. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R and Kreisberg JI: Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8: 1168-1171, 2002. (Pubitemid 35177371)
24. Kurose K, Zhou XP, Araki T, Cannistra SA, Maher ER and Eng C: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158: 2097-2106, 2001. (Pubitemid 32545195)
25. Lawlor MA and Alessi DR: PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903-2910, 2001. (Pubitemid 32821530)
26. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98: 10983-10985, 2001. (Pubitemid 32928669)
27. Scheid MP and Woodgett JR: PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2: 760-768, 2001. (Pubitemid 33679838)
28. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Bernstam F: Targeting mTOR synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042, 2004. (Pubitemid 39383055)
29. Yau CY, Wheeler JJ, Sutton KL and Hedley DW: Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibit PI3K/PKB/mTOR, STAT3 and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenograft. Cancer Res 65: 1497-1504, 2005.
30. Beuvink I, Boulay A, Fumagalli S, et al: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120: 747-759, 2005. (Pubitemid 40568794)
31. Yamamoto S, Tomita Y, Hoshida Y, et al: Prognostic significant of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10: 2846-2850, 2004. (Pubitemid 38509164)
32. Dai DL, Martinka M and Li G: Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J Clin Oncol 23: 1473-1482, 2005.
33. Vasko V, Saji M, Hardy E, et al: Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 41: 161-170, 2004. (Pubitemid 38333792)
34. Avruch J, Belham C, Weng Q, Hara K and Yonezawa K: The p70S6 kinase integrates nutrient and growth signals to control translational capacity. Prog Mol Subcell Biol 26: 115-154, 2001.
35. Inoki K, Corradetti MN and Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24, 2005. (Pubitemid 40070934)
36. Gingras AC, Raught B and Sonenberg N: eIF4E initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963, 1999. (Pubitemid 29449212)
37. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW and Sonenberg N: eIF4E-from translation to transformation. Oncogene 23: 3172-3179, 2004. Technology